Technology

Nanoparticle Composition:

The native Adeira Pharma nanoparticles consist of a lipid core surrounded by a surfactant monolayer, all suspended in an aqueous buffer. The active pharmaceutical ingredients (API) may be dissolved or suspended in the lipid core at high concentrations, or attached passively or covalently to the surface. The encapsulating monolayer, which includes pegylated surfactants, can be modified to include a targeting antibody, peptide, or peptidomimetics.

Studies show that the API is safely held almost entirely on or within the nanoparticles, with negligible residual amounts in the aqueous buffer. The nanoparticles are very stable over a wide range of buffer conditions, pH and temperatures (0-120C), allowing for a host of post-formulation surface modifications and chemistries. Targeting and therapeutic antibodies may be conjugated to the nanoparticles, along with peptides and nucleic acids for RNA-based therapeutics. In addition, fragile therapeutic payloads incorporated into the core, such as proteins and nucleic acids, remain safe and sequestered in the core of the nanoparticles until they arrive at their intended destination. Extensive studies with several classes of drugs, including small molecule and peptide therapeutics, have consistently shown the formulations to be stable, highly reproducible, and possessing vigorous efficacy with low toxicity in animal models of disease.